HIGHLIGHTS
- who: -triazole and collaborators from the College of Medicine, Shantou, China have published the article: Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity, in the Journal: (JOURNAL)
- what: The slices were then covered with cover glass, sealed and placed in a Molecular docking studies are conducted to explore the binding modes of icotinib and compound 3l in the active_site of EGFR, and the results are presented in Figure 1. Study of the reason of this difference is in progress. Combining these results, compound 3l represents a new type of lead compound . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.